We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

BDNF Gene Polymorphism and Antidepressants Treatment

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00308893
First Posted: March 30, 2006
Last Update Posted: December 18, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
H. Lundbeck A/S
Information provided by (Responsible Party):
University Hospital, Tours
  Purpose
The main hypothesis is that the therapeutic response and pharmacological resistance to ADs in depressed patients can be associated with a polymorphism for the BDNF gene. The research of allelic forms associated to lesser efficiency or inefficiency of ADs could add to the body of evidence that BDNF mediates the mechanism of action of ADs, and could have important practical implications. We propose to compare in a group of patients with major depression, the allelic variability of the BDNF gene between responders and non-responders after a 3-week period and a 6-week period of SSRI treatment.

Condition Intervention Phase
Depression Genetic: Genetic analysis Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Brain Derived Neurotrophic Factor (BDNF) Gene Polymorphism and Response to Antidepressants Treatment in Major Depression

Resource links provided by NLM:


Further study details as provided by University Hospital, Tours:

Primary Outcome Measures:
  • Score on Montgomery and Asberg Depression Rating Scale (MADRS) [ Time Frame: At 3 weeks and 6 weeks ]

Enrollment: 188
Study Start Date: July 2006
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Escitalopram
Treatment response after 3 and 6 weeks
Genetic: Genetic analysis
Compare BDNF polymorphism among responders and non-responders

Detailed Description:
  • The main objective is to research an association between polymorphism for the BDNF gene and the 3-week and 6-week response to a SSRI treatment (escitalopram) in major depression.
  • A case control pilot study without any direct individual benefit (200 patients).
  • Study period: 24 months.
  • Scores from reliable and validated psychometric scales (Montgomery and Asberg Depression Scale, Mini International Neuropsychiatric Interview) specifically analysing depression dimension at the time of inclusion, after three and six weeks of antidepressant treatment.
  • Genetic analysis researching a polymorphism of the BDNF gene is done by a blood sample at the baseline.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient suffering a severe depressive episode (according to DSM-IV), evolving since at least 2 weeks before entering the study
  • Age superior to 18 years
  • Caucasian type
  • In absence of any medicinal treatment that could enhance depression: methyldopa, beta-blockers, reserpine,
  • In absence of hypothyroidia or anaemia
  • Without comorbidity that could affect therapy response : e.g. food disorder, substance abuse or dependence syndrome

Exclusion Criteria:

- Will be excluded from the study the patients for which a modification of the depression diagnosis (according to the DSM-IV criteria) takes place during the period of study

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00308893


Locations
France
CPU CHRU de Tours
Tours, France, 37044
Sponsors and Collaborators
University Hospital, Tours
H. Lundbeck A/S
Investigators
Principal Investigator: Wissam EL HAGE, MD, PhD UNIVERSITY HOSPITAL OF TOURS
  More Information

Responsible Party: University Hospital, Tours
ClinicalTrials.gov Identifier: NCT00308893     History of Changes
Other Study ID Numbers: AOHP05-WEH/BDNF
First Submitted: March 28, 2006
First Posted: March 30, 2006
Last Update Posted: December 18, 2013
Last Verified: December 2013

Keywords provided by University Hospital, Tours:
Antidepressants
escitalopram
Genetic polymorphism

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Antidepressive Agents
Citalopram
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation